The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Open accessAbstract
Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 × 10(6) CAR-transduced T cells per kg (dose 1), 3 × 10(6) CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 × 10(6) CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3·0-36·3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldrick's Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationMorgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cited by
Sorted by citations
Items 101–200 of 1,006
Hurton, L. V., Singh, H., Najjar, A. M., Switzer, K. C., Mi, T., Maiti, S. N., Olivares, S., Rabinovich, B. A., Huls, H. M., Forget, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610544113 · Cited by 462
Self-citationParker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N. E., Liu, F., Gabunia, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.022 · Cited by 464
Kim, M. Y., Yu, K., Kenderian, S. S., Ruella, M., Chen, S., Shin, T., Aljanahi, A. A., Schreeder, D. M., Klichinsky, M., Shestova, O. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.013 · Cited by 467
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., Zhang, R., Xiong, Z., Wei, Z., Shen, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.010 · Cited by 463
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 459
Engineering and Design of Chimeric Antigen Receptors
Guedan, S., Calderón, H., Posey, A. D., & Maus, M. V. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 471
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 451
Self-citationYu, Y., Yang, X., Wu, X., & Fan, Y. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.646554 · Cited by 447
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Self-citationD’Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D. B., Glod, J. W., Kaplan, R. N., Grupp, S. A., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 436
Self-citationProgramming CAR-T cells to kill cancer
Labanieh, L., Majzner, R. G., & Mackall, C. L. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0235-9 · Cited by 450
Self-citationJacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K. M., Gryder, B. E., Qin, H., Yang, Y., Chien, C. D., Seif, A. E., Lei, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12320 · Cited by 438
Self-citationThompson, J. A., Schneider, B. J., Brahmer, J. R., Achufusi, A., Armand, P. A., Berkenstock, M., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0020 · Cited by 445
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421
Self-citationOncolytic viruses as engineering platforms for combination immunotherapy
Twumasi‐Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 430
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Engineered T Cell Therapy for Cancer in the Clinic
Zhao, L., & Cao, Y. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02250 · Cited by 430
Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M. R., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 413
Park, J. H., Geyer, M. B., & Brentjens, R. J. (2016) · Blood · doi:10.1182/blood-2016-02-629063 · Cited by 411
CAR-T cells: the long and winding road to solid tumors
D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0278-6 · Cited by 412
Hay, K. A., Gauthier, J., Hirayama, A. V. V., Voutsinas, J. M., Wu, Q. V., Li, D., Gooley, T. A., Cherian, S., Chen, X., Pender, B. S., et al. (2019) · Blood · doi:10.1182/blood-2018-11-883710 · Cited by 412
Early and late hematologic toxicity following CD19 CAR-T cells
Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M. J., Schachter, J., Shimoni, A., Nagler, A., Toren, A., & Jacoby, E. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0487-3 · Cited by 412
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Porter, D. L., Frey, N. V., Wood, P. A., Weng, Y., & Grupp, S. A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0571-y · Cited by 406
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Frey, N. V., & Porter, D. L. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.756 · Cited by 415
Adoptive cellular therapies: the current landscape
Rohaan, M. W., Wilgenhof, S., & Haanen, J. B. A. G. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2484-0 · Cited by 422
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y. J., Ramadoss, N. S., Hardy, I. R., Schulman, A. D., Du, J., Wang, F., Singer, O., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524155113 · Cited by 404
A versatile system for rapid multiplex genome-edited CAR T cell generation
Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 404
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Cappell, K. M., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00530-z · Cited by 414
Self-citationNew development in CAR-T cell therapy
Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0423-1 · Cited by 406
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391
Hu, Q., Li, H., Ogunnaike, E. A., Chen, Q., Ruan, H., Ahn, S., Dukhovlinova, E., Kang, Y., Wen, D., Dotti, G., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00712-1 · Cited by 393
A guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 403
Emerging Cellular Therapies for Cancer
Guedan, S., Ruella, M., & June, C. H. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 394
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A. Y., Meng, N., Dyson, K. A., Grippin, A., Deleyrolle, L. P., Zhang, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11869-4 · Cited by 392
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 385
Walker, A. J., Majzner, R. G., Zhang, L., Wanhainen, K. M., Long, A. H., Nguyen, S. M., Lopomo, P., Vigny, M., Fry, T. J., Orentas, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.008 · Cited by 396
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V. S., Hocker, J. D., Dougherty, S. C., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 389
Self-citationChimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells
Cheung, A. S., Zhang, D. K. Y., Koshy, S. T., & Mooney, D. J. (2018) · Nature Biotechnology · doi:10.1038/nbt.4047 · Cited by 384
Ramos, C. A., Ballard, B. C., Zhang, H., Dakhova, O., Gee, A. P., Mei, Z., Bilgi, M., Wu, M.-F., Liu, H., Grilley, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94306 · Cited by 379
Self-citationBenjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci‐Danicar, O., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32334-5 · Cited by 387
Yakoub‐Agha, I., Chabannon, C., Bader, P., Basak, G. W., Bonig, H. B., Ciceri, F., Corbacioglu, S., Duarte, R. F., Einsele, H., Hudecek, M., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.229781 · Cited by 382
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 372
Self-citationMueller, K. T., Maude, S. L., Porter, D. L., Frey, N. V., Wood, P. A., Han, X., Waldron, E. K., Chakraborty, A., Awasthi, R., Levine, B. L., et al. (2017) · Blood · doi:10.1182/blood-2017-06-786129 · Cited by 367
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Alvi, R. M., Frigault, M. J., Fradley, M. G., Jain, M. D., Mahmood, S., Awadalla, M., Lee, D. H., Zlotoff, D. A., Zhang, L., Drobni, Z. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.038 · Cited by 367
Self-citationLong-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
Shah, N. N., Lee, D. W., Yates, B., Yuan, C. M., Shalabi, H., Martin, S. C., Wolters, P. L., Steinberg, S. M., Baker, E. H., Delbrook, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02262 · Cited by 360
Self-citationEngineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri, A. J., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 379
Davenport, A. J., Cross, R. S., Watson, K. A., Liao, Y., Shi, W., Prince, H. M., Beavis, P. A., Trapani, J. A., Kershaw, M. H., Ritchie, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716266115 · Cited by 361
Alabanza, L. M., Pegues, M. A., Geldres, C., Shi, V. J., Wiltzius, J. J. W., Sievers, S. A., Yang, S., & Kochenderfer, J. N. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.013 · Cited by 363
Self-citationXu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02664 · Cited by 360
Rodríguez-García, A., Lynn, R. C., Poussin, M., Eiva, M. A., Shaw, L. C., O’Connor, R. S., Minutolo, N. G., Casado‐Medrano, V., López, G., Matsuyama, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20893-2 · Cited by 354
Perna, F., Berman, S., Soni, R. K., Mansilla‐Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 356
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Finney, O. C., Brakke, H., Rawlings-Rhea, S., Hicks, R., Doolittle, D., Lopez, M., Futrell, B., Orentas, R. J., Li, D., Gardner, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125423 · Cited by 346
Self-citationAvanzi, M. P., Yeku, O., Li, X., Wijewarnasuriya, D., van Leeuwen, D. G., Cheung, K., Park, H., Purdon, T. J., Daniyan, A. F., Spitzer, M. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.051 · Cited by 359
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349
Davis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30023-1 · Cited by 337
Self-citationCoexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 351
Wang, C., Wu, Z., Wang, Y., Guo, Y., Dai, H., Wang, X., Li, X., Zhang, Y.-J., Zhang, W., Chen, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 335
Santomasso, B., Bachier, C. R., Westin, J. R., Rezvani, K., & Shpall, E. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238691 · Cited by 336
Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0230 · Cited by 329
Self-citationEpigenetic regulation of T cell exhaustion
Belk, J. A., Dániel, B., & Satpathy, A. T. (2022) · Nature Immunology · doi:10.1038/s41590-022-01224-z · Cited by 346
Dai, H., Wu, Z., Jia, H., Tong, C., Guo, Y., Ti, D., Han, X., Liu, Y., Zhang, W., Wang, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00856-8 · Cited by 338
Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., Lin, A., Schlom, J., June, C. H., & Sherwin, S. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0222-9 · Cited by 328
Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 328
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321
Self-citationNinomiya, S., Narala, N., Huye, L. E., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 324
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 347
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Cappell, K. M., Sherry, R. M., Yang, J. C.-H., Goff, S. L., Vanasse, D., McIntyre, L. S., Rosenberg, S. A., & Kochenderfer, J. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01467 · Cited by 315
Self-citationUniversal CARs, universal T cells, and universal CAR T cells
Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0677-2 · Cited by 324
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N. M., Hamieh, M., Hegde, M. G., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 318
Self-citationThe immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
CAR T cells: Continuation in a revolution of immunotherapy
Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303
Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Singh, N., Perazzelli, J., Grupp, S. A., & Barrett, D. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5222 · Cited by 303
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 304
Theruvath, J. L., Sotillo, E., Mount, C., Graef, C. M., Delaidelli, A., Heitzeneder, S., Labanieh, L., Dhingra, S., Leruste, A., Majzner, R. G., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0821-8 · Cited by 305
Self-citationChimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Dai, H., Wang, Y., Lu, X., & Han, W. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv439 · Cited by 312
Ramos, C. A., Rouce, R. H., Robertson, C. S., Reyna, A., Narala, N., Vyas, G., Mehta, B., Zhang, H., Dakhova, O., Carrum, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.009 · Cited by 312
Self-citationSingh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0813 · Cited by 295
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Jabbour, E. J., O'Brien, S. M., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Cancer · doi:10.1002/cncr.29383 · Cited by 299
Gomes‐Silva, D., Mukherjee, M., Srinivasan, M., Krenciute, G., Dakhova, O., Zheng, Y., Cabral, J. M. S., Rooney, C. M., Orange, J. S., Brenner, M. K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.015 · Cited by 293
Gardner, R. A., Ceppi, F., Rivers, J. M., Annesley, C., Summers, C. N., Taraseviciute, A., Gust, J., Leger, K. J., Tarlock, K., Cooper, T. M., et al. (2019) · Blood · doi:10.1182/blood.2019001463 · Cited by 282
Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C. A., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001511 · Cited by 287
Self-citationCatch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Ruella, M., & Maus, M. V. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.003 · Cited by 292
Siegler, E. L., & Kenderian, S. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01973 · Cited by 295
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Yang, J. C.-H., Sherry, R. M., Feldman, S. A., McIntyre, L. S., Bot, A. I., Rossi, J. M., Lam, N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.004 · Cited by 290
Self-citationHu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., Wei, G., Han, L., Wang, H., Yu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3863 · Cited by 296
Lu, Y., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 288
Self-citationCurran, K. J., Margossian, S. P., Kernan, N. A., Silverman, L. B., Williams, D. A., Shukla, N. N., Kobos, R., Forlenza, C. J., Steinherz, P. G., Prockop, S. E., et al. (2019) · Blood · doi:10.1182/blood.2019001641 · Cited by 281
Bhoj, V. G., Arhontoulis, D. C., Wertheim, G. B. W., Capobianchi, J., Callahan, C. A., Ellebrecht, C. T., Obstfeld, A. E., Lacey, S. F., Melenhorst, J. J., Nazimuddin, F., et al. (2016) · Blood · doi:10.1182/blood-2016-01-694356 · Cited by 282
Duell, J., Dittrich, M. T., Bedke, T., Mueller, T., Eisele, F., Rosenwald, A., Rasche, L., Hartmann, E., Dandekar, T., Einsele, H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.41 · Cited by 279
Park, J. H., Romero, F. A. R., Taur, Y., Sadelain, M., Brentjens, R. J., Hohl, T. M., & Seo, S. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy152 · Cited by 282
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Ramos, C. A., Savoldo, B., Torrano, V., Ballard, B. C., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R. T., Gee, A. P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86000 · Cited by 284
Self-citationDrent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J. D., Martens, A. C., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.024 · Cited by 281
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., et al. (2020) · Blood · doi:10.1182/blood.2020005278 · Cited by 279
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Wang, Z., & Han, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0116-0 · Cited by 280
Doran, S. L., Stevanović, S., Adhikary, S., Gartner, J. J., Jia, L., Kwong, M. L. M., Faquin, W. C., Hewitt, S. M., Sherry, R. M., Yang, J. C.-H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02424 · Cited by 283
Self-citationThe Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 279
The evolving concept of liver cancer stem cells
Nio, K., Yamashita, T., & Kaneko, S. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0572-9 · Cited by 278
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Qin, H., Ramakrishna, S., Nguyen, S. M., Fountaine, T. J., Ponduri, A., Stetler‐Stevenson, M., Yuan, C. M., Haso, W. M., Shern, J. F., Shah, N. N., et al. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.10.006 · Cited by 280
Self-citationOptimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E. C., Gill, S. I., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01892 · Cited by 273
Self-citation
Metadata
- Authors
- Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., & Mackall, C. L.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- University of Nevada, Reno (US)
- University of Southern California (US)
- Corresponding author
- Mackall, Crystal L
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 385
- Issue
- 9967
- Pages
- 517-528
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7065359
- OpenAlex
- W2129702476
- Cited by
- 2,898
- References
- 37
- Citations by year
- 2026: 86 · 2025: 154 · 2024: 175 · 2023: 217 · 2022: 275 · 2021: 311 · 2020: 350 · 2019: 317 · 2018: 315 · 2017: 314 · 2016: 232 · 2015: 134
- FWCI
- 103.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. Baldrick's Foundation
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (Z01BC011072, Z01BC010566, Z01BC011024)
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 chimeric antigen receptor, CAR T-cell therapy, acute lymphoblastic leukemia, non-Hodgkin lymphoma, relapsed or refractory B-cell malignancies, maximum tolerated dose, cytokine release syndrome, neurotoxicity, non-relapse mortality, fludarabine and cyclophosphamide conditioning
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Chimera, Feasibility Studies, Female, Humans, Infant, Lymphoma, Non-Hodgkin, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Cohort Studies, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
